Company profile for HengRui

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

HengRui USA is a wholly owned subsidiary of our parent company Jiangsu Hengrui Medicine. The foundation of HengRui USA is rooted in our parent company Jiangsu Hengrui Medicine’s rich heritage of over 200 pipelines and products across therapeutic areas such as oncology, metabolics, autoimmune, pain management, etc. Our work here at HengRui USA focuses on the multiple stages of the drug development process, from a clinical, r...
HengRui USA is a wholly owned subsidiary of our parent company Jiangsu Hengrui Medicine. The foundation of HengRui USA is rooted in our parent company Jiangsu Hengrui Medicine’s rich heritage of over 200 pipelines and products across therapeutic areas such as oncology, metabolics, autoimmune, pain management, etc. Our work here at HengRui USA focuses on the multiple stages of the drug development process, from a clinical, regulatory, and pre-commercialization perspective. HengRui USA operates as the U.S. hub for our parent company from our home office location in Princeton, NJ.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
400 Alexander Park Dr, Princeton, NJ 08540
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/04/3180679/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Announce-Additional-Data-from-Phase-3-Obesity-Trial-in-China-of-Dual-GLP-1-GIP-Receptor-Agonist-HRS9531.html

GLOBENEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/10/21/3170042/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Announce-Phase-3-HRS9531-Obesity-Data-Presentation-at-ObesityWeek-2025.html

GLOBENEWSWIRE
21 Oct 2025

https://www.prnewswire.com/news-releases/live-from-esmo--hengrui-debuts-exhibition-booth-with-landmark-data-showcasing-pharmas-emerging-innovation-power-302588729.html

PR NEWSWIRE
20 Oct 2025

https://www.fiercebiotech.com/biotech/hengruis-glp-1gip-agonist-reports-18-weight-loss-phase-3-trial-readies-china-push

FIERCE BIOTECH
16 Jul 2025

https://www.globenewswire.com/news-release/2025/07/15/3115481/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Report-Positive-Topline-Data-from-Phase-3-Obesity-Trial-in-China-of-Dual-GLP-1-GIP-Receptor-Agonist-HRS9531.html

GLOBENEWSWIRE
15 Jul 2025

https://www.fiercepharma.com/pharma/fda-rejects-hengrui-elevars-pd-1-cancer-drug-combination-again

FIERCE PHARMA
22 Mar 2025

ABOUT THIS PAGE

Contact HengRui and get a quotation

HengRui is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of COREY 16 bulk with DMF offered by HengRui

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty